Robert W. Baird set a $28.00 price objective on Coherus Biosciences (NASDAQ:CHRS) in a research note released on Wednesday morning, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also weighed in on the stock. Credit Suisse Group set a $25.00 price objective on shares of Coherus Biosciences and gave the company a buy rating in a research note on Thursday, March 7th. ValuEngine raised shares of Coherus Biosciences from a hold rating to a buy rating in a research note on Monday, February 4th. Maxim Group reaffirmed a buy rating and issued a $25.00 price objective on shares of Coherus Biosciences in a research note on Monday, April 8th. Zacks Investment Research raised shares of Coherus Biosciences from a sell rating to a hold rating in a research note on Wednesday, January 9th. Finally, BidaskClub raised shares of Coherus Biosciences from a sell rating to a hold rating in a research note on Thursday, January 31st. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $28.00.

NASDAQ:CHRS opened at $14.78 on Wednesday. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 8.29. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.59 and a beta of 3.62. Coherus Biosciences has a 12 month low of $8.32 and a 12 month high of $20.66.

In other Coherus Biosciences news, CFO Jean-Frederic Viret sold 3,000 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $14.92, for a total value of $44,760.00. Following the transaction, the chief financial officer now directly owns 13,185 shares of the company’s stock, valued at $196,720.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 19.57% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in CHRS. Wells Fargo & Company MN lifted its stake in shares of Coherus Biosciences by 7.5% in the third quarter. Wells Fargo & Company MN now owns 264,068 shares of the biotechnology company’s stock valued at $4,358,000 after buying an additional 18,313 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Coherus Biosciences by 14.8% during the third quarter. Bank of New York Mellon Corp now owns 213,776 shares of the biotechnology company’s stock valued at $3,527,000 after purchasing an additional 27,489 shares in the last quarter. BlackRock Inc. lifted its position in shares of Coherus Biosciences by 11.7% during the third quarter. BlackRock Inc. now owns 4,627,525 shares of the biotechnology company’s stock valued at $76,354,000 after purchasing an additional 483,443 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Coherus Biosciences during the third quarter valued at about $282,000. Finally, Dynamic Technology Lab Private Ltd lifted its position in shares of Coherus Biosciences by 156.0% during the third quarter. Dynamic Technology Lab Private Ltd now owns 35,343 shares of the biotechnology company’s stock valued at $583,000 after purchasing an additional 21,538 shares in the last quarter. 94.79% of the stock is currently owned by hedge funds and other institutional investors.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Featured Story: How do candlesticks reflect price movement?

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.